Franck Le Deu retweeted
I recently had the opportunity to discuss BeOne’s global capabilities on Cambridge Associates’ Unseen Upside podcast, including why we invested in building our own global development “superhighway” and what I’ve learned about the power of scientific collaboration across borders.
I hope you’ll listen to the conversation: ow.ly/uFgv5105csv
#UnseenUpside #Oncology #Innovation
Franck Le Deu retweeted
For Bloomberg News Big Take, a deep dive on how biotech startups and pharma giants are increasingly taking trials to China early — and the new and complex challenges they pose.
with @ashleighfurlong @fabiennekatrin and team:
bloomberg.com/news/features/…
Franck Le Deu retweeted
The U.S. Treasury is proposing new restrictions on investments in Chinese biotech, but traditional pharma licensing deals would largely be spared. Equity investments and certain partnerships could face significant hurdles. fiercebiotech.com/biotech/tr…
Franck Le Deu retweeted
How did Hengrui become a go-to source of Chinese biopharma innovation? After multibillion-dollar deals with BMS and GSK, the company's R&D leader tells Fierce what's driving its success and where it goes next. fiercebiotech.com/biotech/he…
Franck Le Deu retweeted
Roche is doubling down on China's Hansoh Pharma with a new ADC deal worth up to $15 billion in milestones. The pact comes just a year after the companies' first collaboration. fiercebiotech.com/biotech/ro… $ROCH.NE
Franck Le Deu retweeted
« Il faut une première à tout et il faut une dernière pour se souvenir, une dernière, juste pour lui. ❤️ »
Merci à @ligue1plus pour LES ÉMOTIONS sur cette bande-annonce de Brest-PSG avec un hommage pour Éric Roy 🇫🇷. 🥹🕊️
Franck Le Deu retweeted
Listen to Episode 44 of @BioVentureVoiCe video podcast w/ Adam Koppel, Partner at @BainCapital. Adam discusses the evolution of biotech investing from the early days of crossover investing to company creation w/ pharma assets and the current strategies out of Bain Capital's Life Sciences private equity fund. The full video is here on @BiotechTV (and also on Spotify and Apple Podcasts): biotechtv.com/post/adam-kopp…
𝐁𝐢𝐨𝐕𝐞𝐧𝐭𝐮𝐫𝐞 𝐕𝐨𝐢𝐂𝐞𝐬: @BainCapital's Adam Koppel discusses both public and private equity investing in biotech, and how the sector has changed over his years in the space.
Full video: biotechtv.com/post/adam-kopp…
Franck Le Deu retweeted
Thoughtful and detailed comments by Alexis Borisy on the China debate, which he has lived from many angles including EQRx, at our conference this week.
Franck Le Deu retweeted
Hengrui rising: Frank Jiang on building a global biotech. On The BioCentury Show, Jiang discusses Hengrui’s R&D scale, global ambitions, and what its GSK and BMS alliances reveal about the next phase of China-originated innovation. buff.ly/soem45G
Franck Le Deu retweeted
Europe's narrow path between the U.S. and China: Europe has an opening to become biotech's third pole, says Franck Le Deu in a BioCentury Guest Commentary, but only if it engages China while anchoring IP, manufacturing, development at home (open access): biocentury.com/article/65981…
Franck Le Deu retweeted
A écouter. Absolument passionnant pour quiconque s’intéresse à la démographie au moment où nous vivons un phénomène mondial sans précédent : Why birth rates are falling everywhere all at once | FT youtu.be/6lFXmDk-tps?is=FaqR… via @YouTube
Franck Le Deu retweeted
My new essay "A Biopharmaceutical Superpower: China’s Rise, Its Limits, and What Comes Next": China’s biopharma revolution is real: once a generics & API giant, it now controls ~80% of global API intermediates, nearly all KSMs for key U.S. drugs, and is closing the gap on innovative pipelines. Record licensing deals topped $135B last year—Pfizer alone paid $1.25B for a Chinese bispecific. 1/3 cirsd.org/horizon-article/a-…
Franck Le Deu retweeted
In support of a multipolar biopharma world. Why a strong U.S. sector can still thrive next to a stronger China: a BioCentury Guest Commentary by Franck Le Deu buff.ly/5BWbKml
Franck Le Deu retweeted
On the latest #BioCenturyThisWeek podcast: Toward a multipolar biopharma world. Why a strong U.S. sector can still thrive next to a stronger China. Plus: Stargardt therapies in focus & @SteveUsdin1’s take on @US_FDA buff.ly/r9snjhA
Franck Le Deu retweeted
Caldera Therapeutics Launches with $112.5 Million and Announces First Subjects Dosed in Phase 1 Trial of First-In-Class Bispecific Antibody CLD-423 for Inflammatory Bowel Disease businesswire.com/news/home/2…
CLD-423/QX030N, a long-acting bispecific antibody targeting the clinically validated IL-23p19 and TL1A pathways, developed by 🇨🇳 Qyuns Therapeutics nitter.gq/chuminhua432/status/19…
A new #NewCo #license deal: 🇨🇳 #Qyuns Therapeutics and NewCo #Caldera Therapeutics have entered into an out-license agreement . The License Agreement grants Caldera Therapeutics an exclusive right to develop and commercialize #QX030N globally. QX030N is a long-acting bispecific antibody in the pre-clinical stage for the treatment of immunologic disorders
Qyuns will be entitled to receive a one-time, non-refundable, and non-creditable upfront payment of USD10 million, and to receive approximately 24.88% of the equity interest in Caldera Therapeutics.
Qyuns Therapeutics may also receive additional payments of up to USD545 million, subject to the achievement of certain clinical development, regulatory and commercial milestones. The Group will also be entitled to receive tiered royalties on net sales from Caldera Therapeutics during a specified time period after the first commercial sales of QX030N. hkexnews.hk/listedco/listcon…
Franck Le Deu retweeted
The boom has turned to bust for China’s vaccine industry. Market darlings that built empires on the back of blockbuster HPV vaccines reported staggering losses, while even makers of more modest flu and tetanus shots saw profits evaporate. caixinglobal.com/2025-09-29/…
Franck Le Deu retweeted
just back from shanghai / beijing / HK, met several chinese pharma, 10+ biotechs, local VCs -
notes / comments from the trip:
* what China did to ab's / bispecifics / TCEs, they are about to do (or already have) to genetic medicines
* there are now 120+ "in vivo CAR-T" companies in China; only a small handful will ultimately survive
* HK public market has had a huge run in 1H 2025 (hangseng biotech index up from 6,500 to ~11,000), although has taken a breather very recently
* Every chinese pharma gunning for "going global" but face challenges with global clinical dev capital intensity and limited commercial infra; "next gen Takeda" is the goal
* newco model rampant in late 24 / early 25 has largely fallen out of favor given China funding environment currently arguably better than US and chinese co's are incentivized to take assets further / straight to large pharma
* however, out-licensing conversations still active for those that can get economics to work
* US advantage remains: depth of capital markets, clinical development, translational biology






















